A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3.

@article{Jimenez2005ARF,
  title={A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3.},
  author={Xenia Jimenez and Dan Lu and Laura Brennan and Kris Persaud and Meilin Liu and Huaquan Miao and Larry Witte and Zhenping Zhu},
  journal={Molecular cancer therapeutics},
  year={2005},
  volume={4 3},
  pages={427-34}
}
Vascular endothelial growth factors (VEGF) and their receptors (VEGFR) have been implicated to play important roles in tumor-associated angiogenesis and lymphangiogenesis, and hence in tumor growth and metastasis. We previously produced a number of fully human antibodies directed against VEGF receptor 2 (VEGFR2) and VEGF receptor 3 (VEGFR3) and showed that these antibodies are capable of inhibiting growth factor (VEGF and VEGF-C)-induced receptor activation, migration, and proliferation of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Involvement of vascular Molecular Cancer Therapeutics 433 Mol Cancer Ther 2005;4(3)

  • H Kubo, T Fujiwara, L Jussila
  • March 2005 Research. on October
  • 2005
1 Excerpt

Involvement of vascular Molecular Cancer Therapeutics 433

  • H Kubo, T Fujiwara, L Jussila
  • Mol Cancer Ther
  • 2005

Similar Papers

Loading similar papers…